FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109442703> ?p ?o ?g. }

• W3109442703 abstract "Introduction: Chronic, broad-spectrum immunosuppressive therapy (IST) can be associated with side effects in many people with generalized myasthenia gravis (gMG), and treatment guidelines recommend that the IST dose be tapered once patients achieve a stable treatment response. We therefore examined IST use in eculizumab-treated patients with refractory gMG. Methods: The REGAIN open-label extension (OLE) enrolled 117 adults with refractory anti-acetylcholine receptor antibody-positive gMG who had completed the 6-month, randomized, double-blind, placebo-controlled REGAIN study of eculizumab. Eligible patients had received ≥2 ISTs for ≥1 year or ≥1 IST with intravenous immunoglobulin or plasma exchange ≥4 times in 1 year, without symptom control. During REGAIN, changes in concomitant MG therapies were not permitted; during the OLE, they were permitted at the investigators' discretion. Participants received eculizumab 1,200 mg every 2 weeks for up to 4 years; concomitant prednisone and related corticosteroids (PRED), azathioprine (AZA), and mycophenolate mofetil (MMF) use was recorded. Changes in MG Activities of Daily Living and Quantitative MG total scores, MG exacerbations, and adverse events were also recorded. Results: At last OLE assessment, 88.0% (103/117) of participants were using ≥1 IST vs. 98.3% (115/117) at OLE baseline. During the OLE, 76.9% (90/117) of patients experienced a total of 719 IST changes. Almost half of participants [48.7% (57/117)] stopped or decreased ≥1 IST owing to MG symptom improvement, representing 38.9% (280/719) of all changes. In patients who decreased and/or stopped ≥1 IST, mean daily doses of PRED, AZA, and MMF decreased between OLE baseline and last assessment by 60.8% [standard deviation (SD), 28.07; P &lt; 0.0001], 89.1% (SD, 25.77; P &lt; 0.0001), and 56.0% (SD, 32.99; P &lt; 0.0001), respectively. Improved clinical outcomes were observed with eculizumab regardless of IST changes during the OLE, and eculizumab's safety profile was similar in patients who used PRED, AZA, and MMF. Conclusions: Use of ISTs by patients with previously refractory gMG decreased during eculizumab treatment in the REGAIN OLE. Clinical improvements with eculizumab were maintained by patients in all groups, including those who decreased and/or stopped concomitant ISTs. Trial registration: www.clinicaltrials.gov : NCT01997229, NCT02301624." @default.
• W3109442703 created "2020-12-07" @default.
• W3109442703 creator A5002850283 @default.
• W3109442703 creator A5004702963 @default.
• W3109442703 creator A5029156957 @default.
• W3109442703 creator A5055671145 @default.
• W3109442703 creator A5069281297 @default.
• W3109442703 creator A5070602040 @default.
• W3109442703 date "2020-11-24" @default.
• W3109442703 modified "2023-10-16" @default.
• W3109442703 title "Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study" @default.
• W3109442703 cites W1561559732 @default.
• W3109442703 cites W1722566242 @default.
• W3109442703 cites W1983404333 @default.
• W3109442703 cites W1995289926 @default.
• W3109442703 cites W2000124365 @default.
• W3109442703 cites W2010750774 @default.
• W3109442703 cites W2017235356 @default.
• W3109442703 cites W2023377972 @default.
• W3109442703 cites W2028176861 @default.
• W3109442703 cites W2054753234 @default.
• W3109442703 cites W2057817095 @default.
• W3109442703 cites W2065357689 @default.
• W3109442703 cites W2067350327 @default.
• W3109442703 cites W2068030815 @default.
• W3109442703 cites W2085694036 @default.
• W3109442703 cites W2117697429 @default.
• W3109442703 cites W2118510193 @default.
• W3109442703 cites W2123731102 @default.
• W3109442703 cites W2146831407 @default.
• W3109442703 cites W2461303519 @default.
• W3109442703 cites W2766784006 @default.
• W3109442703 cites W2912901461 @default.
• W3109442703 cites W2914587352 @default.
• W3109442703 cites W3009559238 @default.
• W3109442703 cites W3011996040 @default.
• W3109442703 cites W4295682875 @default.
• W3109442703 doi "https://doi.org/10.3389/fneur.2020.556104" @default.
• W3109442703 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7732596" @default.
• W3109442703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33329303" @default.
• W3109442703 hasPublicationYear "2020" @default.
• W3109442703 type Work @default.
• W3109442703 sameAs 3109442703 @default.
• W3109442703 citedByCount "11" @default.
• W3109442703 countsByYear W31094427032021 @default.
• W3109442703 countsByYear W31094427032022 @default.
• W3109442703 countsByYear W31094427032023 @default.
• W3109442703 crossrefType "journal-article" @default.
• W3109442703 hasAuthorship W3109442703A5002850283 @default.
• W3109442703 hasAuthorship W3109442703A5004702963 @default.
• W3109442703 hasAuthorship W3109442703A5029156957 @default.
• W3109442703 hasAuthorship W3109442703A5055671145 @default.
• W3109442703 hasAuthorship W3109442703A5069281297 @default.
• W3109442703 hasAuthorship W3109442703A5070602040 @default.
• W3109442703 hasBestOaLocation W31094427031 @default.
• W3109442703 hasConcept C111684460 @default.
• W3109442703 hasConcept C121332964 @default.
• W3109442703 hasConcept C126322002 @default.
• W3109442703 hasConcept C142424586 @default.
• W3109442703 hasConcept C142724271 @default.
• W3109442703 hasConcept C159654299 @default.
• W3109442703 hasConcept C197934379 @default.
• W3109442703 hasConcept C203014093 @default.
• W3109442703 hasConcept C204787440 @default.
• W3109442703 hasConcept C27081682 @default.
• W3109442703 hasConcept C2776760755 @default.
• W3109442703 hasConcept C2777991916 @default.
• W3109442703 hasConcept C2778105408 @default.
• W3109442703 hasConcept C2778720950 @default.
• W3109442703 hasConcept C2779134260 @default.
• W3109442703 hasConcept C2779384505 @default.
• W3109442703 hasConcept C71924100 @default.
• W3109442703 hasConcept C87355193 @default.
• W3109442703 hasConcept C90924648 @default.
• W3109442703 hasConceptScore W3109442703C111684460 @default.
• W3109442703 hasConceptScore W3109442703C121332964 @default.
• W3109442703 hasConceptScore W3109442703C126322002 @default.
• W3109442703 hasConceptScore W3109442703C142424586 @default.
• W3109442703 hasConceptScore W3109442703C142724271 @default.
• W3109442703 hasConceptScore W3109442703C159654299 @default.
• W3109442703 hasConceptScore W3109442703C197934379 @default.
• W3109442703 hasConceptScore W3109442703C203014093 @default.
• W3109442703 hasConceptScore W3109442703C204787440 @default.
• W3109442703 hasConceptScore W3109442703C27081682 @default.
• W3109442703 hasConceptScore W3109442703C2776760755 @default.
• W3109442703 hasConceptScore W3109442703C2777991916 @default.
• W3109442703 hasConceptScore W3109442703C2778105408 @default.
• W3109442703 hasConceptScore W3109442703C2778720950 @default.
• W3109442703 hasConceptScore W3109442703C2779134260 @default.
• W3109442703 hasConceptScore W3109442703C2779384505 @default.
• W3109442703 hasConceptScore W3109442703C71924100 @default.
• W3109442703 hasConceptScore W3109442703C87355193 @default.
• W3109442703 hasConceptScore W3109442703C90924648 @default.
• W3109442703 hasFunder F4320309052 @default.
• W3109442703 hasLocation W31094427031 @default.
• W3109442703 hasLocation W31094427032 @default.
• W3109442703 hasLocation W31094427033 @default.
• W3109442703 hasOpenAccess W3109442703 @default.
• W3109442703 hasPrimaryLocation W31094427031 @default.
• W3109442703 hasRelatedWork W1989394588 @default.

• next